Catalina Barcelo1, Manel Aouri2, Perrine Courlet1, Monia Guidi1,3, Dominique L Braun4,5, Huldrych F Günthard4,5, Rein J Piso6, Matthias Cavassini7, Thierry Buclin1, Laurent A Decosterd1, Chantal Csajka1,3. 1. Service of Clinical Pharmacology, University Hospital Centre and University of Lausanne, Bugnon 17, Lausanne, Switzerland. 2. Service of Clinical Chemistry, University Hospital Centre and University of Lausanne, Bugnon 46, Lausanne, Switzerland. 3. School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Michel-Servet 1, Geneva, Switzerland. 4. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Rämistrasse 100, Zurich, Switzerland. 5. Institute of Medical Virology, University of Zurich, Winterthurerstrasse 190, Zurich 8057, Switzerland. 6. Division of Infectious Diseases, Department of Medicine, Cantonal Hospital of Olten, Baslerstrasse 150, Olten, Switzerland. 7. Service of Infectious Diseases, University Hospital Centre and University of Lausanne, Bugnon 46, Lausanne, Switzerland.
Abstract
OBJECTIVES: Dolutegravir is widely prescribed owing to its potent antiviral activity, high genetic barrier and good tolerability. The aim of this study was to characterize dolutegravir's pharmacokinetic profile and variability in a real-life setting and to identify individual factors and co-medications affecting dolutegravir disposition. METHODS: A population pharmacokinetic model was developed using NONMEM®. Relevant demographic factors, clinical factors and co-medications were tested as potential covariates. Simulations based on the final model served to compare expected dolutegravir concentrations under standard and alternative dosage regimens in the case of drug-drug interactions. RESULTS: A total of 620 dolutegravir plasma concentrations were collected from 521 HIV-infected individuals under steady-state conditions. A one-compartment model with first-order absorption and elimination best characterized dolutegravir pharmacokinetics. Typical dolutegravir apparent clearance (CL/F) was 0.93 L/h with 32% between-subject variability, the apparent volume of distribution was 20.2 L and the absorption rate constant was fixed to 2.24 h-1. Older age, higher body weight and current smoking were associated with higher CL/F. Atazanavir co-administration decreased dolutegravir CL/F by 38%, while darunavir modestly increased CL/F by 14%. Rifampicin co-administration showed the largest impact on CL/F. Simulations suggest that average dolutegravir trough concentrations are 63% lower after 50 mg/12h with rifampicin compared with a standard dosage of 50 mg/24h without rifampicin. Average trough concentrations after 100 mg/24h and 100 mg/12h with rifampicin are 92% and 25% lower than the standard dosage without rifampicin, respectively. CONCLUSIONS: Patients co-treated with dolutegravir and rifampicin might benefit from therapeutic drug monitoring and individualized dosage increase, up to 100 mg/12 h in some cases.
OBJECTIVES:Dolutegravir is widely prescribed owing to its potent antiviral activity, high genetic barrier and good tolerability. The aim of this study was to characterize dolutegravir's pharmacokinetic profile and variability in a real-life setting and to identify individual factors and co-medications affecting dolutegravir disposition. METHODS: A population pharmacokinetic model was developed using NONMEM®. Relevant demographic factors, clinical factors and co-medications were tested as potential covariates. Simulations based on the final model served to compare expected dolutegravir concentrations under standard and alternative dosage regimens in the case of drug-drug interactions. RESULTS: A total of 620 dolutegravir plasma concentrations were collected from 521 HIV-infected individuals under steady-state conditions. A one-compartment model with first-order absorption and elimination best characterized dolutegravir pharmacokinetics. Typical dolutegravir apparent clearance (CL/F) was 0.93 L/h with 32% between-subject variability, the apparent volume of distribution was 20.2 L and the absorption rate constant was fixed to 2.24 h-1. Older age, higher body weight and current smoking were associated with higher CL/F. Atazanavir co-administration decreased dolutegravir CL/F by 38%, while darunavir modestly increased CL/F by 14%. Rifampicin co-administration showed the largest impact on CL/F. Simulations suggest that average dolutegravir trough concentrations are 63% lower after 50 mg/12h with rifampicin compared with a standard dosage of 50 mg/24h without rifampicin. Average trough concentrations after 100 mg/24h and 100 mg/12h with rifampicin are 92% and 25% lower than the standard dosage without rifampicin, respectively. CONCLUSIONS:Patients co-treated with dolutegravir and rifampicin might benefit from therapeutic drug monitoring and individualized dosage increase, up to 100 mg/12 h in some cases.
Authors: Aida N Kawuma; Roeland E Wasmann; Kelly E Dooley; Marta Boffito; Gary Maartens; Paolo Denti Journal: Antimicrob Agents Chemother Date: 2022-05-23 Impact factor: 5.938
Authors: Matthew L Romo; Ellen Brazier; Dominique Mahambou-Nsondé; Reneé De Waal; Christine Sekaggya-Wiltshire; Cleophas Chimbetete; Winnie R Muyindike; Gad Murenzi; Cordelia Kunzekwenyika; Thierry Tiendrebeogo; Josephine A Muhairwe; Patricia Lelo; Anastase Dzudie; Christelle Twizere; Idiovino Rafael; Oliver C Ezechi; Lameck Diero; Marcel Yotebieng; Lukas Fenner; Kara K Wools-Kaloustian; N Sarita Shah; Denis Nash Journal: J Int AIDS Soc Date: 2022-07 Impact factor: 6.707
Authors: Alyson S Smith; Soneela Ankam; Chen Farhy; Lorenzo Fiengo; Ranor C B Basa; Kara L Gordon; Charles T Martin; Alexey V Terskikh; Kelly L Jordan-Sciutto; Jeffrey H Price; Patrick M McDonough Journal: J Pharmacol Toxicol Methods Date: 2022-02-08 Impact factor: 2.285
Authors: Joseph Piscitelli; Mina Nikanjam; Brookie M Best; Edward Acosta; Mark Mirochnick; Diana F Clarke; Edmund V Capparelli; Jeremiah D Momper Journal: J Acquir Immune Defic Syndr Date: 2022-01-01 Impact factor: 3.771
Authors: Chi-Hua Lu; Edward M Bednarczyk; Linda M Catanzaro; Alyssa Shon; Jia-Chen Xu; Qing Ma Journal: Curr Res Pharmacol Drug Discov Date: 2021-08-08